Collegium Pharmaceutical (COLL) investor relations material

Executive summary

• Achieved record 2025 revenue of $780.6M, up 24% year-over-year, with strong growth in both pain management and neuropsychiatry portfolios, notably Jornay PM® (ADHD), which saw 48% revenue growth and 20% prescription growth over 2024.

• Closed a $980M syndicated credit facility, repaid $581M in prior debt, improved interest rates, and ended 2025 with $386.7M in cash and marketable securities.

• Returned $25M to shareholders via share repurchases and continued disciplined capital deployment.

• Leadership changes included new Chairman and two new board members, plus key executive appointments.

• Published fourth annual ESG report, highlighting progress in sustainability, community engagement, and employee development.

Voting matters and shareholder proposals

• Election of eight director nominees for one-year terms expiring at the 2027 annual meeting.

• Advisory vote to approve named executive officer compensation (say-on-pay).

• Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Seven of eight directors are independent; all committees are fully independent.

• Board refreshment with new Chairman and two new directors; average director tenure is 6.7 years and average age is 69.

• Board committees include Audit, Compliance, Compensation, Nominating & Corporate Governance, and Transaction Committees.

• Annual director self-evaluations and robust risk oversight practices in place.

• Code of Ethics and active shareholder engagement policies.